The growth of antimicrobial-resistant nosocomial infections (ARNI) necessitates the identification and widespread implementation of effective interventions to reduce their incidence, such as changes in prescribing and improvements in infection control. Candidate interventions are often identified by observational studies of modifiable risk factors for ARNI; candidates are then evaluated in clinical trials. Existing methods for both observational studies and clinical trials assume that patient outcomes are independent of each other. This is not true for ARNI, because pathogens are transmissible, so infection of one host may make others more likely to be infected; similarly, use of antibiotics by others in the hospital can increase an individual's risk of ARNI, even if s/he has not received the drug. We have shown that nonindependence is common in ARNI data, obscures the mechanistic effects of antimicrobial use on the incidence of ARNI, and can lead to false results (negative or positive) when interventions are assessed; thus, there is an emerging consensus on the inadequacy of many existing studies and the need for better methods. We will develop and test methods for observational studies and clinical trials that account for nonindependence of patients. For observational studies, we will use data from the University of Utah (UU) to assess simultaneously the effects of individual antibiotic use and total hospital-wide use on risk of ARNI. For clinical trials, we will develop three methods for evaluating interventions while accounting for nonindependence. We will test these methods on real data from UU and the CDC/Emory ICARE project, and on simulated data, for their fit to data, ability to detect effective interventions, and ability to avoid false positive detection of intervention effects that are not real. Methods will include an auto regressive negative binomial model, which is easily implemented in standard software, and more sophisticated approaches, such as hidden Markov models. We will identify methods that perform well on data and will reliably determine the effectiveness of interventions. Dissemination of the results of these studies via peer-reviewed publications, free distribution of software, didactic seminars and future work with specific collaborators will aid in the reliable identification of candidate interventions and trustworthy ways to assess whether these interventions work. This will in turn lead to better practices to reduce the incidence of ARNI.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI055825-02
Application #
6732688
Study Section
Special Emphasis Panel (ZAI1-AR-M (M1))
Program Officer
Peters, Kent
Project Start
2003-04-15
Project End
2006-03-31
Budget Start
2004-04-01
Budget End
2006-03-31
Support Year
2
Fiscal Year
2004
Total Cost
$204,844
Indirect Cost
Name
Harvard University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Palmer, Michael E; Lipsitch, Marc (2006) The influence of hitchhiking and deleterious mutation upon asexual mutation rates. Genetics 173:461-72
Cohen, Ted; Lipsitch, Marc; Walensky, Rochelle P et al. (2006) Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A 103:7042-7
Cepeda, Jorge A; Whitehouse, Tony; Cooper, Ben et al. (2005) Isolation of patients in single rooms or cohorts to reduce spread of MRSA in intensive-care units: prospective two-centre study. Lancet 365:295-304
Cooper, Ben; Lipsitch, Marc (2004) The analysis of hospital infection data using hidden Markov models. Biostatistics 5:223-37
Lipsitch, Marc; Cohen, Ted; Cooper, Ben et al. (2003) Transmission dynamics and control of severe acute respiratory syndrome. Science 300:1966-70